title: Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
abstract: Oritavancin is an investigational lipoglycopeptide in clinical development for the treatment of acute bacterial skin and skin structure infections. In this study, we demonstrate that oritavancin causes bacterial membrane depolarization and permeabilization leading to cell death of Gram-positive pathogens and that these effects are attributable to the 4'-chlorobiphenylmethyl group of the molecule.
authors.affiliation: The Medicines Company, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1. adam.belley@themedco.com
authors.forename: Adam
authors.initials: A
authors.lastname: Belley
authors.forename: Geoffrey A
authors.initials: GA
authors.lastname: McKay
authors.forename: Francis F
authors.initials: FF
authors.lastname: Arhin
authors.forename: Ingrid
authors.initials: I
authors.lastname: Sarmiento
authors.forename: Sylvain
authors.initials: S
authors.lastname: Beaulieu
authors.forename: Ibthihal
authors.initials: I
authors.lastname: Fadhil
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Parr
authors.forename: Gregory
authors.initials: G
authors.lastname: Moeck
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects*; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000187:drug effects*; D006020:Glycopeptides / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology* / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D014640:Vancomycin; C100708:oritavancin